---
title: Regeneron Pharmaceuticals, Inc. (REGN)
layout: default
nav_order: 170
---

# Regeneron Pharmaceuticals, Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 4/5

{: .label .label-blue }

Understandability: 4/5

{: .label .label-green }

Balance Sheet Health: 5/5

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=REGN+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/REGN/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning }
>The moat, understandability, and balance sheet health scores reflect a conservative evaluation to ensure a margin of safety in any assessment.



{: .important }
Regeneron boasts a strong economic moat built upon its intellectual property, leading-edge scientific expertise, and strong relationships with key healthcare providers.

**Business Overview:**

*   **Revenue Streams:** The company primarily generates revenue from sales of its marketed products, mainly EYLEA (a medication for age-related macular degeneration, among other eye disorders), Dupixent (an antibody for treating atopic dermatitis, asthma, etc.), Libtayo (an immunotherapy for skin cancer) and Praluent (for lowering cholesterol). A smaller portion of its revenue comes from collaborations with other pharmaceutical companies.
*   **Industry Trends**: The pharmaceutical industry is characterized by intense competition, high R&D costs, significant regulatory hurdles, and long development cycles. The rise of biologics, such as antibodies and immunotherapies, has led to new treatment options with greater efficacy but also greater manufacturing complexity and production costs. In addition, as patents expire, companies will face generic and biosimilar competition, eroding their revenue.
*   **Margins**: Regeneron's operating margins are relatively high, reflecting the strong profitability of its key products. However, like other biotech companies, its profit margins can be sensitive to pricing pressures, changing reimbursement policies and high development expenses.
*  **Competitive Landscape**: Regeneron operates in a highly competitive market landscape, with many companies focusing on development of new and innovative treatments. Strong competitors include companies like Novartis, Pfizer, and Amgen, that compete across several different indications. In addition, smaller firms can compete in specific niches.
*   **What Makes Regeneron Different**: The company's core competency in antibody drug discovery and biologics manufacturing gives it a notable competitive advantage. It also has an extensive pipeline that has several promising compounds. They also have strong collaborations with companies such as Sanofi, Bayer, and Teva Pharmaceutical.

{: .important }
Regeneron's focus on cutting-edge scientific research and development, coupled with a successful track record of developing and commercializing innovative medicines, has given it a substantial edge over peers.

**Financials Analysis:**

*   **Income Statement**: For the quarter ended September 30, 2023, Regeneron reported total revenues of $3.413 billion, a 14% increase year-over-year. Revenue was driven by strong sales of EYLEA ($1.6 billion), Dupixent ($2.9 billion, sales with Sanofi are shared), and Libtayo ($83 million). Net income was \$1.2 billion, a 31% increase year-over-year. R&D costs were $1.8 billion, reflecting the heavy investments in development of new products and clinical trials. Operating margin for 2023 is 38.96%, up from 34.37% in 2022.
*   **Balance Sheet**: The company boasts a very healthy balance sheet as of September 30, 2023, with more than $12 billion in cash and marketable securities and with negligible debt. They also have a strong current ratio of 2.13. This highlights the financial strength and stability of the company. They continue to build cash reserves and their balance sheet appears to be better than most firms.
*   **Cash Flow Statement**: Regeneron's cash flow from operations is consistently positive and strong. For the first nine months of 2023, cash flow from operations was $3.8 billion. This indicates that the company generates enough funds to meet its operational and investing requirements. 

{: .new }
**Recent Concerns/Controversies/Problems**:
While the overall performance is very strong, Regeneron has been facing some challenges. Competitor products like Vabysmo have started to take market share away from EYLEA. Furthermore, ongoing clinical trials for new medicines remain uncertain, and have a risk of failure.
However, the management has also said that it has been investing aggressively into its pipeline and is moving forward with its business plan and is also confident in their long-term prospects.

**Moat Rating: 4/5**
The following factors contribute to Regeneron's moat:
*   **Intellectual Property**: The company has a large portfolio of patents and trade secrets which create a strong competitive advantage.
*   **Scientific Expertise**: Regeneron has expertise in antibody drug discovery and manufacturing which are very hard to replicate.
*   **Regulatory Approvals:** The companyâ€™s ability to navigate and obtain regulatory approvals is also a moat.
*  **Collaborations and Partnerships:** A lot of Regeneron's revenue is tied to collaboration with other pharmaceutical giants such as Sanofi and Bayer, which gives them access to marketing strength and also reduces risk.

However, they also face a lot of competition which makes the moat susceptible to erosion. Thus, I believe they are a strong company, but not invincible.

**Understandability Rating: 4/5**

Regeneron has a fairly diversified portfolio of products as well as a robust pipeline in different disease areas. Though the financials are easy to understand, there is still some complexity when you start to look at their various collaborations and future projections. Therefore, it has a score of 4/5.

**Balance Sheet Health Rating: 5/5**

The company has an extremely healthy balance sheet, with high levels of cash and marketable securities. It also has extremely limited debt. Therefore, I give it a top score of 5/5.

{: .important }
The biggest danger to Regeneron is the unpredictability of clinical trials. Even with a robust pipeline, some projects may not be successful, which could lead to big drops in profits and revenues. Furthermore, there is the ever present danger of competitive threats and patent expirations.
